FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968656375> ?p ?o ?g. }

• W1968656375 endingPage "3060" @default.
• W1968656375 startingPage "3054" @default.
• W1968656375 abstract "BACKGROUND: In what to the authors' knowledge is the first such study for a pediatric cancer, a large database was retrospectively analyzed to assess statistically the likelihood of response to a given salvage therapy in different clinical subsets of patients. METHODS: Treatment was comprised of high-dose cyclophosphamide (at a dose of 140 mg/kg), topotecan (at a dose of 8 mg/m2), and vincristine (at a dose of 0.067 mg/kg or 2 mg/m2, whichever was lower; maximum dose, 2 mg) (HD-CTV). The Fisher exact test was used for comparisons of response rates among standard subsets of patients (n = 126) with refractory or recurrent neuroblastoma (NB). RESULTS: Among children, major (ie, complete/partial) responses occurred in 11 of 58 (19%) with primary refractory NB, 4 of 14 (29%) with secondary refractory NB, 13 of 25 (52%) with a new (first) disease recurrence, and none of 13 patients with progressive disease (PD) while receiving therapy. Other children had mixed responses (MRs); when combining major responses and MRs, anti-NB activity was noted in 26 of 58 (45%) children with primary refractory NB, 10 of 14 (71%) children with secondary refractory NB, 20 of 25 (80%) children with a new (first) disease recurrence, and 1 of 13 (8%) children with PD while receiving therapy. The response rate was significantly different across the 4 groups of children for both major responses (P = .003) and combined responses (P = .001). All 10 adolescents/adults treated for primary refractory NB had no response, which was a significantly inferior result compared with the response rate of 45% noted in children with primary refractory NB (P = .008). CONCLUSIONS: Response to HD-CTV as salvage therapy is significantly less likely in adolescents/adults and in children with NB that is persistent or progressing on treatment rather than newly recurrent off treatment. These findings are broadly applicable and should be considered when designing, and interpreting the results of, phase 2 studies. Cancer 2010. © 2010 American Cancer Society." @default.
• W1968656375 created "2016-06-24" @default.
• W1968656375 creator A5006374965 @default.
• W1968656375 creator A5034081882 @default.
• W1968656375 creator A5034325765 @default.
• W1968656375 creator A5043729995 @default.
• W1968656375 creator A5050680844 @default.
• W1968656375 date "2010-04-01" @default.
• W1968656375 modified "2023-09-25" @default.
• W1968656375 title "Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma" @default.
• W1968656375 cites W1750107794 @default.
• W1968656375 cites W1901103115 @default.
• W1968656375 cites W1935226228 @default.
• W1968656375 cites W1965114854 @default.
• W1968656375 cites W1965304621 @default.
• W1968656375 cites W1968030467 @default.
• W1968656375 cites W1968522647 @default.
• W1968656375 cites W1979904309 @default.
• W1968656375 cites W2005354295 @default.
• W1968656375 cites W2007680507 @default.
• W1968656375 cites W2012797500 @default.
• W1968656375 cites W2024383854 @default.
• W1968656375 cites W2032775628 @default.
• W1968656375 cites W2033485414 @default.
• W1968656375 cites W2057975969 @default.
• W1968656375 cites W2058419064 @default.
• W1968656375 cites W2068167166 @default.
• W1968656375 cites W2068830230 @default.
• W1968656375 cites W2085743994 @default.
• W1968656375 cites W2096398040 @default.
• W1968656375 cites W2104684902 @default.
• W1968656375 cites W2111733282 @default.
• W1968656375 cites W2112654701 @default.
• W1968656375 cites W2113695682 @default.
• W1968656375 cites W2131352716 @default.
• W1968656375 cites W2132154679 @default.
• W1968656375 cites W2136574608 @default.
• W1968656375 cites W2155254558 @default.
• W1968656375 cites W2167974749 @default.
• W1968656375 cites W2273425405 @default.
• W1968656375 doi "https://doi.org/10.1002/cncr.25232" @default.
• W1968656375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20564411" @default.
• W1968656375 hasPublicationYear "2010" @default.
• W1968656375 type Work @default.
• W1968656375 sameAs 1968656375 @default.
• W1968656375 citedByCount "36" @default.
• W1968656375 countsByYear W19686563752012 @default.
• W1968656375 countsByYear W19686563752013 @default.
• W1968656375 countsByYear W19686563752014 @default.
• W1968656375 countsByYear W19686563752015 @default.
• W1968656375 countsByYear W19686563752016 @default.
• W1968656375 countsByYear W19686563752017 @default.
• W1968656375 countsByYear W19686563752018 @default.
• W1968656375 countsByYear W19686563752019 @default.
• W1968656375 countsByYear W19686563752020 @default.
• W1968656375 countsByYear W19686563752022 @default.
• W1968656375 countsByYear W19686563752023 @default.
• W1968656375 crossrefType "journal-article" @default.
• W1968656375 hasAuthorship W1968656375A5006374965 @default.
• W1968656375 hasAuthorship W1968656375A5034081882 @default.
• W1968656375 hasAuthorship W1968656375A5034325765 @default.
• W1968656375 hasAuthorship W1968656375A5043729995 @default.
• W1968656375 hasAuthorship W1968656375A5050680844 @default.
• W1968656375 hasConcept C121332964 @default.
• W1968656375 hasConcept C126322002 @default.
• W1968656375 hasConcept C142424586 @default.
• W1968656375 hasConcept C2776694085 @default.
• W1968656375 hasConcept C2776715637 @default.
• W1968656375 hasConcept C2776755627 @default.
• W1968656375 hasConcept C2778822529 @default.
• W1968656375 hasConcept C2779429289 @default.
• W1968656375 hasConcept C2780775027 @default.
• W1968656375 hasConcept C2781209748 @default.
• W1968656375 hasConcept C54355233 @default.
• W1968656375 hasConcept C71924100 @default.
• W1968656375 hasConcept C81885089 @default.
• W1968656375 hasConcept C86803240 @default.
• W1968656375 hasConcept C87355193 @default.
• W1968656375 hasConcept C90924648 @default.
• W1968656375 hasConceptScore W1968656375C121332964 @default.
• W1968656375 hasConceptScore W1968656375C126322002 @default.
• W1968656375 hasConceptScore W1968656375C142424586 @default.
• W1968656375 hasConceptScore W1968656375C2776694085 @default.
• W1968656375 hasConceptScore W1968656375C2776715637 @default.
• W1968656375 hasConceptScore W1968656375C2776755627 @default.
• W1968656375 hasConceptScore W1968656375C2778822529 @default.
• W1968656375 hasConceptScore W1968656375C2779429289 @default.
• W1968656375 hasConceptScore W1968656375C2780775027 @default.
• W1968656375 hasConceptScore W1968656375C2781209748 @default.
• W1968656375 hasConceptScore W1968656375C54355233 @default.
• W1968656375 hasConceptScore W1968656375C71924100 @default.
• W1968656375 hasConceptScore W1968656375C81885089 @default.
• W1968656375 hasConceptScore W1968656375C86803240 @default.
• W1968656375 hasConceptScore W1968656375C87355193 @default.
• W1968656375 hasConceptScore W1968656375C90924648 @default.
• W1968656375 hasIssue "12" @default.
• W1968656375 hasLocation W19686563751 @default.
• W1968656375 hasLocation W19686563752 @default.

• next